Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01357421 | Effects of TT301 on Cytokine Levels Post Endotoxin Challenge | PHASE1 | COMPLETED | 18 | — | — | May 1, 2011 | Jun 1, 2011 | Jun 6, 2013 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| TT301 | EXPERIMENTAL | Investigational drug TT301 |
| Placebo | PLACEBO_COMPARATOR | Normal saline |
| Name | Type | Description |
|---|---|---|
| TT301 | DRUG | Single iv dose of TT301 |
| Placebo | DRUG | Single iv dose of 0.9% sodium chloride for injection USP |
Inclusion Criteria: * Male * 18 to 40 years, inclusive * 55 - 95 kg, inclusive Exclusion Criteria: * Evidence of any clinically significant disease * History of cancer * History of syncope or severe vasovagal events * Antibiotic treatment within 60 days of Day 1 * Surgical procedure within 60 day...